Clinical investigation of receptor and non-receptor tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer

Expert Opinion on Pharmacotherapy

Volumn 14, Issue 16, 2013, Pages 2171-2182

  Klempner, Samuel J ^a   Myers, Andrea P ^a,b   Mills, Gordon B ^c   Westin, Shannon N ^c  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

angiogenesis; ovarian cancer; Phase III; signaling; targeted therapy; tyrosine kinase

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CEDIRANIB; DOCETAXEL; DOXORUBICIN; ERLOTINIB; GEMCITABINE; NINTEDANIB; PACLITAXEL; PAZOPANIB; PLATINUM DERIVATIVE; PROTEIN TYROSINE KINASE INHIBITOR; SARACATINIB; TAXANE DERIVATIVE; TOPOTECAN;

ANGIOGENESIS; AREA UNDER THE CURVE; CANCER CHEMOTHERAPY; DIARRHEA; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; HUMAN; HYPERTRANSAMINASEMIA; MONOTHERAPY; NAUSEA; OVARY CARCINOMA; PERITONEUM CANCER; REVIEW; UTERINE TUBE CARCINOMA; VOMITING;

ANTINEOPLASTIC AGENTS; BENZODIOXOLES; FEMALE; HUMANS; INDOLES; NEOPLASMS, GLANDULAR AND EPITHELIAL; NEOVASCULARIZATION, PATHOLOGIC; OVARIAN NEOPLASMS; PROTEIN KINASE INHIBITORS; PYRIMIDINES; QUINAZOLINES; SULFONAMIDES;

EID: 84885604991     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2013.826650     Document Type: Review

References (118)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62(1):10-29
2. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334(1):1-6 (Pubitemid 26012496)
3. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: a phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer (from the Gynecologic Oncology Group). Semin Oncol 1996;23(5 Suppl 12):40-7 (Pubitemid 26391379)
4. Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006;354(1):34-43 . Important Phase III trial establishing survival benefit of intraperitoneal chemotherapy in EOC. (Pubitemid 43048949)
5. Guarneri V, Piacentini F, Barbieri E, Conte PF. Achievements and unmet needs in the management of advanced ovarian cancer. Gynecol Oncol 2010;117(2):152-8
6. Vergote I, Trope CG, Amant F, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 2010;363(10):943-53
7. Jaaback K, Johnson N. Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. Cochrane Database Syst Rev 2006(1):CD005340
8. Hess LM, Benham-Hutchins M, Herzog TJ, et al. A meta-analysis of the efficacy of intraperitoneal cisplatin for the front-line treatment of ovarian cancer. Int J Gynecol Cancer 2007;17(3):561-70 (Pubitemid 46744010)
9. Markman M. Intraperitoneal chemotherapy is appropriate first line therapy for patients with optimally debulked ovarian cancer. Crit Rev Oncol Hematol 2001;38(3):171-5 (Pubitemid 32451677)
10. Katsumata N, Yasuda M, Takahashi F, et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet 2009;374(9698):1331-8
11. du Bois A, Quinn M, Thigpen T, et al. 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann Oncol 2005;16(Suppl 8):viii7-viii12 (Pubitemid 41631227)
12. Thigpen T, Stuart G, du Bois A, et al. Clinical trials in ovarian carcinoma: requirements for standard approaches and regimens. Ann Oncol 2005;16(Suppl 8):viii13-19 (Pubitemid 41631228)
13. Bristow RE, Tomacruz RS, Armstrong DK, et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 2002;20(5):1248-59 (Pubitemid 34177431)
14. Chi DS, Eisenhauer EL, Lang J, et al. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC) Gynecol Oncol 2006;103(2):559-64 (Pubitemid 44602167)
15. du Bois A, Reuss A, Pujade-Lauraine E, et al. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire(GINECO). Cancer 2009;115(6):1234-44
16. Mei L, Chen H, Wei DM, et al. Maintenance chemotherapy for ovarian cancer. Cochrane Database Syst Rev 2010(9):CD007414
17. Sabbatini P, Harter P, Scambia G, et al. Abagovomab As Maintenance Therapy in Patients With Epithelial Ovarian Cancer: a Phase III Trial of the AGO OVAR, COGI, GINECO, and GEICOThe MIMOSA Study. J Clin Oncol 2013;31(12):1554-61
18. Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011;365(26):2473-83 . Important Phase III trials demonstrating improved PFS but no OS benefit with bevacizumab.
19. Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011;365(26):2484-96 . Important Phase III trials demonstrating improved PFS but no OS benefit with bevacizumab.
20. Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, et al. Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol 2010;28(20):3323-9
21. Wagner U, Marth C, Largillier R, et al. Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients. Br J Cancer 2012;107(4):588-91
22. Pfisterer J, Plante M, Vergote I, et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol 2006;24(29):4699-707 (Pubitemid 46630933)
23. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology, Ovarian Cancer vI. Version 1. 2013. Available from: http://www.nccn. org/professionals/physician-gls/pdf/ovarian.pdf 2013 [cited 2013 04/27/2013]
24. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100(1):57-70 (Pubitemid 30046295)
25. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144(5):646-74
26. Ramakrishnan S, Subramanian IV, Yokoyama Y, Geller M. Angiogenesis in normal and neoplastic ovaries. Angiogenesis 2005;8(2):169-82 (Pubitemid 41712846)
27. Thanapprapasr D, Hu W, Sood AK, Coleman RL. Moving beyond VEGF for anti-angiogenesis strategies in gynecologic cancer. Curr Pharm Des 2012;18(19):2713-19 . Nice review on methods of targeting angiogenesis in ovarian and other gynecologic cancers.
28. Liu J, Matulonis UA. Anti-angiogenic agents in ovarian cancer: dawn of a new era Curr Oncol Rep 2011;13(6):450-8
29. Chen CA, Cheng WF, Lee CN, et al. Serum vascular endothelial growth factor in epithelial ovarian neoplasms: correlation with patient survival. Gynecol Oncol 1999;74(2):235-40
30. Chen H, Ye D, Xie X, et al. VEGF, VEGFRs expressions and activated STATs in ovarian epithelial carcinoma. Gynecol Oncol 2004;94(3):630-5 (Pubitemid 39194453)
31. Ye F, Chen HZ, Xie X, et al. Vascular endothelial growth factor (VEGF) and ovarian carcinoma cell supernatant activate signal transducers and activators of transcription (STATs) via VEGF receptor-2 (KDR) in human hemopoietic progenitor cells. Gynecol Oncol 2004;94(1):125-33 (Pubitemid 38950508)
32. Delli Carpini J, Karam AK, Montgomery L. Vascular endothelial growth factor and its relationship to the prognosis and treatment of breast, ovarian, and cervical cancer. Angiogenesis 2010;13(1):43-58
33. Han ES, Burger RA, Darcy KM, et al. Predictive and prognostic angiogenic markers in a gynecologic oncology group phase II trial of bevacizumab in recurrent and persistent ovarian or peritoneal cancer. Gynecol Oncol 2010;119(3):484-90
34. Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer 2008;8(8):579-91
35. Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2002;2(10):795-803 (Pubitemid 37328914)
36. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008;8(8):592-603 .. Excellent review of established resistance mechanisms to angiogenesis inhibitors.
37. Casanovas O, Hicklin DJ, Bergers G, Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005;8(4):299-309 (Pubitemid 41443415)
38. Brown JM, Wilson WR. Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 2004;4(6):437-47 (Pubitemid 38745529)
39. Harris AL. Hypoxiaa key regulatory factor in tumour growth. Nat Rev Cancer 2002;2(1):38-47 (Pubitemid 37328806)
40. Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 2004;4(1):71-8 (Pubitemid 38082155)
41. Grunewald M, Avraham I, Dor Y, et al. VEGF-induced adult neovascularization: recruitment, retention, and role of accessory cells. Cell 2006;124(1):175-89 (Pubitemid 43069318)
42. Du R, Lu KV, Petritsch C, et al. HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell 2008;13(3):206-20 (Pubitemid 351318372)
43. Nimeiri HS, Oza AM, Morgan RJ, et al. Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia. Gynecol Oncol 2008;110(1):49-55
44. Smerdel MP, Steffensen KD, Waldstrom M, et al. The predictive value of serum VEGF in multiresistant ovarian cancer patients treated with bevacizumab. Gynecol Oncol 2010;118(2):167-71
45. McMeekin DS, Sill MW, Benbrook D, et al. A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group study. Gynecol Oncol 2007;105(2):508-16 (Pubitemid 46591977)
46. Jubb AM, Hurwitz HI, Bai W, et al. Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, andmicrovessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. J Clin Oncol 2006;24(2):217-27 (Pubitemid 46622051)
47. Jubb AM, Oates AJ, Holden S, Koeppen H. Predicting benefit from anti-angiogenic agents in malignancy. Nat Rev Cancer 2006;6(8):626-35 (Pubitemid 44140860)
48. Hasselbalch B, Eriksen JG, Broholm H, et al. Prospective evaluation of angiogenic, hypoxic and EGFR-related biomarkers in recurrent glioblastoma multiforme treated with cetuximab, bevacizumab and irinotecan. APMIS 2010;118(8):585-94
49. Wedge SR, Kendrew J, Hennequin LF, et al. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res 2005;65(10):4389-400 (Pubitemid 40775678)
50. Brave SR, Ratcliffe K, Wilson Z, et al. Assessing the activity of cediranib, a VEGFR-2/3 tyrosine kinase inhibitor, against VEGFR-1 and members of the structurally related PDGFR family. Mol Cancer Ther 2011;10(5):861-73
51. Drevs J, Siegert P, Medinger M, et al. Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors. J Clin Oncol 2007;25(21):3045-54 (Pubitemid 47218051)
52. Chen E, Jonker D, Gauthier I, et al. Phase I study of cediranib in combination with oxaliplatin and infusional 5-Fluorouracil in patients with advanced colorectal cancer. Clin Cancer Res 2009;15(4):1481-6
53. Goss G, Shepherd FA, Laurie S, et al. A phase I and pharmacokinetic study of daily oral cediranib, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer: a study of the National Cancer Institute of Canada Clinical Trials Group. Eur J Cancer 2009;45(5):782-8
54. Matulonis UA, Berlin S, Ivy P, et al. Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. J Clin Oncol 2009;27(33):5601-6
55. Goss GD, Arnold A, Shepherd FA, et al. Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study. J Clin Oncol 2010;28(1):49-55
56. Ramalingam SS, Belani CP, Mack PC, et al. Phase II study of Cediranib (AZD 2171), an inhibitor of the vascular endothelial growth factor receptor, for second-line therapy of small cell lung cancer (National Cancer Institute #7097). J Thorac Oncol 2010;5(8):1279-84
57. Hoff PM, Hochhaus A, Pestalozzi BC, et al. Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II). J Clin Oncol 2012;30(29):3596-603
58. Schmoll HJ, Cunningham D, Sobrero A, et al. Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III). J Clin Oncol 2012;30(29):3588-95
59. Presta M, Dell'Era P, Mitola S, et al. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev 2005;16(2):159-78 (Pubitemid 40616114)
60. Fernando NT, Koch M, Rothrock C, et al. Tumor escape from endogenous, extracellular matrix-associated angiogenesis inhibitors by up-regulation of multiple proangiogenic factors. Clin Cancer Res 2008;14(5):1529-39 . Preclinical example of compensatory changes leading to acquired resistance to angiogenesis inhibition. (Pubitemid 351413938)
61. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med 2000;6(4):389-95 (Pubitemid 30208155)
62. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000;407(6801):249-57
63. Erber R, Thurnher A, Katsen AD, et al. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J 2004;18(2):338-40
64. Hilberg F, Roth GJ, Krssak M, et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res 2008;68(12):4774-82
65. Mross K, Stefanic M, Gmehling D, et al. Phase I study of the angiogenesis inhibitor BIBF 1120 in patients with advanced solid tumors. Clin Cancer Res 2010;16(1):311-19
66. Ledermann JA, Hackshaw A, Kaye S, et al. Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer. J Clin Oncol 2011;29(28):3798-804
67. du Bois A, Huober J, Stopfer P, et al. A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies. Ann Oncol 2010;21(2):370-5
68. Kumar R, Knick VB, Rudolph SK, et al. Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol Cancer Ther 2007;6(7):2012-21 (Pubitemid 47052491)
69. Hurwitz HI, Dowlati A, Saini S, et al. Phase I trial of pazopanib in patients with advanced cancer. Clin Cancer Res 2009;15(12):4220-7
70. Friedlander M, Hancock KC, Rischin D, et al. A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer. Gynecol Oncol 2010;119(1):32-7
71. Du Bois A, Floquet A, Kim JW, et al. Randomized, double-blind, phase III trial of pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (AEOC): Results of an international Intergroup trial (AGOOVAR16). J Clin Oncol 2013;31:suppl; abstr LBA5503
72. Han LY, Landen CN, Trevino JG, et al. Antiangiogenic and antitumor effects of SRC inhibition in ovarian carcinoma. Cancer Res 2006;66(17):8633-9 (Pubitemid 44449178)
73. Summy JM, Trevino JG, Lesslie DP, et al. AP23846, a novel and highly potent Src family kinase inhibitor, reduces vascular endothelial growth factor and interleukin-8 expression in human solid tumor cell lines and abrogatesdownstream angiogenic processes. Mol Cancer Ther 2005;4(12):1900-11 (Pubitemid 43056973)
74. Martin GS. The hunting of the Src. Nat Rev Mol Cell Biol 2001;2(6):467-75
75. Ledermann JA, Raja FA. Targeted trials in ovarian cancer. Gynecol Oncol 2010;119(1):151-6
76. Wiener JR, Nakano K, Kruzelock RP, et al. Decreased Src tyrosine kinase activity inhibits malignant human ovarian cancer tumor growth in a nude mouse model. Clin Cancer Res 1999;5(8):2164-70 (Pubitemid 29399273)
77. Wiener JR, Windham TC, Estrella VC, et al. Activated SRC protein tyrosine kinase is overexpressed in late-stage human ovarian cancers. Gynecol Oncol 2003;8(1):73-9 (Pubitemid 36062670)
78. Chen T, Pengetnze Y, Taylor CC. Src inhibition enhances paclitaxel cytotoxicity in ovarian cancer cells by caspase-9-independent activation of caspase-3. Mol Cancer Ther 2005;4(2):217-24 (Pubitemid 40340201)
79. Hennequin LF, Allen J, Breed J, et al. N-(5-chloro-1,3-benzodioxol-4-yl)- 7-[2- (4-methylpiperazin-1-yl)ethoxy]-5- (tetrahydro-2H-pyran-4-yloxy) quinazolin- 4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor. J Med Chem 2006;49(22):6465-88 (Pubitemid 44657442)
80. Arcaroli JJ, Quackenbush KS, Powell RW, et al. Common PIK3CA mutants and a novel 3' UTR mutation are associated with increased sensitivity to saracatinib. Clin Cancer Res 2012;18(9):2704-14 . Study highlighting the concept that improved molecular classification can inform response to targeted therapies. njmhh
81. Baselga J, Cervantes A, Martinelli E, et al. Phase I safety, pharmacokinetics, and inhibition of SRC activity study of saracatinib in patients with solid tumors. Clin Cancer Res 2010;16(19):4876-83
82. Kaye S, Aamdal S, Jones R, et al. Phase I study of saracatinib (AZD0530) in combination with paclitaxel and/or carboplatin in patients with solid tumours. Br J Cancer 2012;106(11):1728-34
83. Fury MG, Baxi S, Shen R, et al. Phase II study of saracatinib (AZD0530) for patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). Anticancer Res 2011;31(1):249-53
84. Mackay HJ, Au HJ, McWhirter E, et al. A phase II trial of the Src kinase inhibitor saracatinib (AZD0530) in patients with metastatic or locally advanced gastric or gastro esophageal junction (GEJ) adenocarcinoma: a trial of the PMH phase II consortium. Invest New Drugs 2012;30(3):1158-63
85. McNeish IA, Ledermann J, Webber LC, et al. A randomized placebo-controlled trial of saracatinib (AZD0530) plus weekly paclitaxel in platinum-resistant ovarian, fallopian-tube, or primary peritoneal cancer (SaPPrOC). J Clin Oncol 2013;31:suppl; abstr 5514
86. Psyrri A, Kassar M, Yu Z, et al. Effect of epidermal growth factor receptor expression level on survival in patients with epithelial ovarian cancer. Clin Cancer Res 2005;11(24 Pt 1):8637-43 (Pubitemid 43005911)
87. Bartlett JM, Langdon SP, Simpson BJ, et al. The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer. Br J Cancer 1996;73(3):301-6 (Pubitemid 26047507)
88. Lassus H, Sihto H, Leminen A, et al. Gene amplification, mutation, and protein expression of EGFR and mutations of ERBB2 in serous ovarian carcinoma. J Mol Med (Berl) 2006;84(8):671-81 (Pubitemid 44164262)
89. Cheng L, Zhang S, Alexander R, et al. The landscape of EGFR pathways and personalized management of non-small-cell lung cancer. Future Oncol 2011;7(4):519-41
90. Moyer JD, Barbacci EG, Iwata KK, et al. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res 1997;57(21):4838-48 (Pubitemid 27468992)
91. Gordon AN, Finkler N, Edwards RP, et al. Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study. Int J Gynecol Cancer 2005;15(5):785-92 (Pubitemid 41783082)
92. Vergote I, Joly F, Katsaros D, et al. Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: a GCIG and EORTC-GCG study. J Clin Oncol 2012;30:suppl; abstr LBA5000
93. Vaughan S, Coward JI, et al. Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer 2011;11(10):719-25
94. Cannistra SA, Matulonis UA, Penson RT, et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 2007;25(33):5180-6 (Pubitemid 350232248)
95. Aghajanian C, Blank SV, Goff BA, et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 2012;30(17):2039-45
96. Westin SN, Herzog TJ, Coleman RL. Investigational agents in development for the treatment of ovarian cancer. Invest New Drugs 2013;31(1):213-29 .. Excellent review of compounds in earlier phase development in ovarian cancer.
97. Motzer RJ, Escudier B, Tomczak P, et al. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol 2013;14(6):552-62
98. Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 2011;378(9807):1931-9
99. Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010;28(6):1061-8
100. Sternberg CN, Hawkins RE, Wagstaff J, et al. A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update. Eur J Cancer 2013;49(6):1287-96
101. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355(23):2408-17 (Pubitemid 44903745)
102. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347(7):472-80 (Pubitemid 34879334)
103. Kalidas M, Kantarjian H, Talpaz M. Chronic myelogenous leukemia. JAMA 2001;286(8):895-8 (Pubitemid 33010322)
104. Mauro MJ, O'Dwyer M, Heinrich MC, Druker BJ. STI571: a paradigm of new agents for cancer therapeutics. J Clin Oncol 2002;20(1):325-34 (Pubitemid 34032628)
105. Janne PA, Engelman JA, Johnson BE. Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology. J Clin Oncol 2005;23(14):3227-34 (Pubitemid 46211347)
106. Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012;13(3):239-46
107. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350(21):2129-39 (Pubitemid 38637993)
108. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010;362(25):2380-8
109. Yang D, Khan S, Sun Y, et al. Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. JAMA 2011;306(14):1557-65
110. Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009;361(2):123-34
111. Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 2012;366(15):1382-92
112. Rigakos G, Razis E. BRCAness: finding the Achilles heel in ovarian cancer. Oncologist 2012;17(7):956-62 . Review demonstrating how improved molecular understanding has predictive and prognositc information in EOC.
113. Dann RB, DeLoia JA, Timms KM, et al. BRCA1/2 mutations and expression: response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer. Gynecol Oncol 2012;125(3):677-82
114. Ahmed AA, Etemadmoghadam D, Temple J, et al. Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J Pathol 2010;221(1):49-56
115. Moreno-Smith M, Halder JB, Meltzer PS, et al. ATP11B mediates platinum resistance in ovarian cancer. J Clin Invest 2013
116. Mitamura T, Watari H, Wang L, et al. Downregulation of miRNA-31 induces taxane resistance in ovarian cancer cells through increase of receptor tyrosine kinase MET. Oncogenesis 2013;2:e40
117. Ratner ES, Keane FK, Lindner R, et al. A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer. Oncogene 2012;31(42):4559-66
118. Kendrew J, Odedra R, Logie A, et al. Anti-tumour and anti-vascular effects of cediranib (AZD2171) alone and in combination with other anti-tumour therapies. Cancer Chemother Pharmacol 2013;71(4):1021-32